Primary Lateral SclerosisSymptoms, Doctors, Treatments, Advances & More
Primary Lateral Sclerosis Overview
Learn About Primary Lateral Sclerosis
- Primary lateral sclerosis
- Adult-onset PLS
- Adult-onset primary lateral sclerosis
Johns Hopkins Outpatient Center
Nicholas Maragakis treats patients with motor neuron diseases, such as amyotrophic lateral sclerosis (ALS). This care is coordinated with the Johns Hopkins Center for ALS Specialty Care, a multidisciplinary clinic with expertise in treating patients with ALS and providing support to their caregivers. He serves as medical director of the ALS Clinical Trials Unit, an extension of the multidisciplinary clinic that seeks to facilitate opportunities for patients with ALS to participate in clinical trials that could advance the treatment of this disease. Dr. Maragakis is interested in the basic science of understanding neurodegenerative diseases, as well as the translational potential of therapeutic compounds developed in the laboratory. His fundamental research interest is in using stem cells — more specifically, stem cell-derived motor neurons and glia — for understanding the development and propagation of ALS. His laboratory has been involved in creating and characterizing lines of stem cells from patients with ALS using induced pluripotent stem cell (iPSC) methodologies. The laboratory has a large library of iPSCs from patients with familial ALS and from patients with sporadic ALS. The utilization of this library of iPSCs has facilitated the development of a spinal cord-specific iPSC-astrocyte/motor neuron co-culture system, which has been leveraged for the development of assays that can be used for both the basic understanding of ALS astrocyte and motor neuron biology as well as, eventually, drug screening for ALS therapeutics. His laboratory has taken its long-standing interests in astrocyte biology, as it relates to ALS, to develop a program that investigates astrocyte-specific mechanisms as contributors to the progression (both temporally and anatomically) of disease in ALS. In this vein, there is an interest in astrocytic glutamate transporters and, more recently, astrocyte hemichannels and gap junctions. Dr. Maragakis is rated as an Elite provider by MediFind in the treatment of Primary Lateral Sclerosis. He is also highly rated in 7 other conditions, according to our data. His clinical expertise encompasses Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, 15q11.2 Microdeletion, and Spinal Muscular Atrophy (SMA).
Emory Brain Health Center
Jonathan Glass is a Neuromusculoskeletal Medicine provider practicing medicine in Atlanta, Georgia. He has been practicing medicine for over 41 years. Dr. Glass is rated as an Elite provider by MediFind in the treatment of Primary Lateral Sclerosis. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, Spinal Muscular Atrophy (SMA), Spinal and Bulbar Muscular Atrophy, and Gastrostomy. Dr. Glass is board certified in American Board Of Pathology, 1997.
BIDMC Department Of Neurology
Seward Rutkove is a Neurologist practicing medicine in Boston, Massachusetts. Dr. Rutkove is rated as an Elite provider by MediFind in the treatment of Primary Lateral Sclerosis. He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Primary Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and Orchiectomy. Dr. Rutkove is board certified in American Board Of Psychiatry And Neurology.
Summary: The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
Summary: The primary objective of the clinical investigation is to demonstrate successful clinical use of the ThecaFlex DRx™ System in delivering nusinersen in subjects with spinal muscular atrophy (SMA). All enrolled subjects will undergo implantation of the investigational device (ThecaFlex DRx™ System) and will be followed for 12 months after receiving the implant. The 12-month data will be used to asse...
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center


